

DOCKET NO: 17044DIV

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Dolly et al.

Examiner: Robert Zeman

Serial No.: 09/676,053

Group Art Unit: 1645

Filed:

September 28, 2000

RECEIVED

For: MODIFICATION OF

CLOSTRIDIAL TOXINS FOR USE AS TRANSPORT PROTEINS

APR 0 3 2003

TECH CENTER 1600/2900 SUBSTITUTE SEQUENCE LISTING AND STATEMENT UNDER 37 CFR

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Applicants are responding to the communication mailed March 18, 2003 in which the Sequence Listing was again made subject to a Notice to Comply because of an unreadable Computer Readable Form of the sequence listing.

Applicants hereby enclose a Substitute Computer Readable Form, as required. The information recorded on the enclosed computer readable form is identical to the written sequence listing filed January 4, 2002. No new matter is present in the Substitute Sequence Listing.

Kindly use our Deposit Account 01-0885 for the payment if there are fees due in connection herewith.

Respectfully submitted,

Dated: 32703

Carlos A. Fisher

Registration No. 36,510

Attorney of Record

ALLERGAN, INC.-T2-7H

2525 Dupont Drive

Irvine, CA 92612

Tel: 714-246-4920

Fax: 714-246-4249

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail with sufficient postage in an envelope addressed to: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202 on:

DONNIE FERGUSON